Risk Factors of Invasive Pulmonary Aspergillosis after Living and Deceased Donor Liver Transplantation and Lessons from Successfully Treated Cases
Not Applicable
Completed
- Conditions
- iver transplantation
- Registration Number
- JPRN-UMIN000041949
- Lead Sponsor
- Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 326
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who could not undergo a liver transplant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie invasive pulmonary aspergillosis (IPA) pathogenesis post-liver transplantation?
How do antifungal treatment strategies for IPA compare to standard-of-care in liver transplant recipients?
What biomarkers are associated with successful outcomes in IPA cases after liver transplantation?
What are the key adverse events observed in IPA management following liver transplantation?
Are there combination therapies or alternative antifungal agents showing promise for IPA treatment post-liver transplant?